Millions on Probation Still Can't Legally Use Medical Marijuana

August 21, 2026

Photo via Unsplash.

Roughly four million American adults are on probation or parole right now -- a population almost double the combined number of people sitting in jails and prisons nationwide. Most of them, even in states with fully operational medical marijuana programs, still cannot legally use cannabis to treat their own conditions without risking reincarceration. That contradiction hasn't gone away with federal rescheduling. If anything, it's gotten more glaring.

When marijuana moved to Schedule III in April 2026, plenty of headlines treated it as a sweeping medical vindication. It wasn't. The order only reclassified marijuana for FDA-approved drug products and cannabis sold under a state medical license -- adult-use marijuana stayed exactly where it was, on Schedule I, and nothing about individual criminal exposure changed. For the millions of people under community supervision, the gap between what rescheduling promised and what it actually delivered isn't abstract. It's the difference between a positive drug test that ends with a warning and one that sends someone back behind bars.

What Rescheduling to Schedule III Actually Changed

Photo by AymaneJed via Pixabay.

The rescheduling order signed by Acting Attorney General Todd Blanche, effective April 28, 2026 upon Federal Register publication, is narrower than most coverage suggested at the time. It moved marijuana to Schedule III in exactly two circumstances: when it's an FDA-approved pharmaceutical product, or when it's cannabis distributed under a state-licensed medical marijuana program. Everything else -- every adult-use purchase, every unlicensed transaction, every gray-market gummy -- remains Schedule I under federal law, full stop.

That distinction matters because a separate, much bigger fight is still unresolved. A DEA administrative hearing on rescheduling marijuana across the board wrapped up July 15, 2026 after eleven days of testimony. Chief Administrative Law Judge Derek Julius gave the parties until August 17 to file closing briefs before he makes a formal recommendation to the DEA Administrator. Worth noting: the DEA invited seven parties opposed to rescheduling into that hearing and zero parties in favor of it, a lopsided lineup that legal observers expect to fuel further litigation regardless of which way the recommendation goes.

Even if the full rescheduling eventually happens, the practical upside for now is concentrated almost entirely on the business side of the industry -- Section 280E tax relief for state-licensed operators and somewhat easier pathways for federally sanctioned research. What Schedule III does not do is decriminalize possession, create a federal medical defense, or shield an individual patient who gets pulled over or drug-tested. The reclassification changed a regulatory category. It didn't touch the criminal code that governs ordinary people's daily lives.

Nearly 4 Million People, One Overlooked Population

Photo via Pexels.

Nearly four million people are under some form of community supervision in the United States -- more people than sit in every jail and prison in the country combined. That population rarely factors into cannabis policy conversations, which tend to focus on dispensary access, banking reform, or interstate commerce. But a July 23, 2026 policy brief from the Reason Foundation, authored by policy analyst Sephria Reynolds-Tanner, argues persuasively that this is exactly backwards -- supervised populations are where the legal contradictions of partial rescheduling land hardest.

Reynolds-Tanner's brief documents something advocates have flagged for years: even states with mature, well-established medical marijuana programs routinely carve out exceptions for people on probation, parole, or supervised release. It doesn't take a new arrest or a new crime to trigger consequences -- a single positive drug test, or documented use without specific court authorization, counts as a technical violation. Technical violations are a leading driver of reincarceration nationally, and cannabis use is one of the most common triggers among them.

The brief's central argument is worth sitting with: now that Schedule III formally acknowledges marijuana has a currently accepted medical use under federal law, state policies that still treat medical cannabis as categorically forbidden for supervised populations lose whatever legal and ethical cover they once had. If the federal government itself recognizes accepted medical use, a state barring a legitimate cardholder from that same medicine solely because of probation status becomes a much harder position to defend -- legally, ethically, or otherwise. The result, as things stand, is a two-tiered system where an identical medical marijuana card carries entirely different real-world protections depending on whether the holder has an open case with the criminal justice system.

A Patchwork of State Rules, From Protective to Punitive

Photo via Unsplash.

State approaches to this problem range from genuinely protective to flatly punitive, and the variation has nothing to do with medical need. Since early 2021, Connecticut, Minnesota, Missouri, New Jersey, New Mexico, and New York have all passed laws that bar probation or parole revocation for cannabis use in most or all circumstances -- a legislative acknowledgment that a positive THC test shouldn't function as a de facto life sentence extension.

Other states split the difference. Colorado generally protects medical cardholders on probation, but carves out an exception for people with prior marijuana convictions, who remain barred from using cannabis while on parole or probation even with a valid card. Michigan took a different route: a 2021 court of appeals ruling held that judges cannot prohibit medical cardholders on probation from using cannabis, and legal experts there have argued the same reasoning logically extends to parolees and people out on bond, even though the legislature hasn't codified it.

Then there's the punitive end. Florida courts and probation officers have consistently treated a physician's medical marijuana recommendation as legally distinct from a prescription -- since cannabis can't be prescribed under federal law -- which means it doesn't qualify for the statutory exception that covers other prescribed medications. Georgia offers no protections whatsoever for supervised individuals holding medical cards, regardless of diagnosis. And federal probation, which governs people convicted of federal crimes, has historically barred any marijuana use outright because the substance remained Schedule I -- a blanket policy that's now arguably overdue for review given the partial rescheduling, though no formal change has been announced.

Why the Legal Contradiction Matters Now

Photo via Pexels.

Rescheduling was marketed, in part, as federal recognition that marijuana has accepted medical value. That recognition apparently stops at the courthouse door for anyone under supervision. It's worth remembering who that population actually is: people on probation and parole are disproportionately low-income, and many are already managing chronic pain or other conditions that physicians commonly recommend cannabis to treat. Denying them access isn't a neutral policy choice -- it's a decision that a criminal record outweighs a medical diagnosis.

The current patchwork means outcomes turn almost entirely on geography. A patient with a legitimate medical card and a documented condition can use their medicine without fear in New Jersey or Minnesota, and face reincarceration for the same behavior in Georgia or Florida. That's not a difference driven by medical evidence -- it's a difference driven by which legislature got around to fixing its probation statute.

The good news, such as it is, is that fixing this doesn't require waiting on Washington. New Jersey, Minnesota, and the others that passed reform since 2021 show the legislative lift is entirely manageable at the state level, and doesn't depend on the outcome of the DEA's pending decision on full rescheduling. That decision, whenever Judge Julius's recommendation lands and however the Administrator rules, won't resolve this issue either. Even a full move to Schedule III or lower wouldn't automatically rewrite a single state's probation code -- those statutes are creatures of state legislatures and state courts, and they'll stay exactly as punitive as lawmakers leave them, no matter what happens in the DEA's hearing room. Anyone relying on their state's specific probation or parole rules should confirm the current law directly, since it varies significantly and continues to shift.

Federal rescheduling was a tax and research fix aimed at license-holding businesses, not a rights fix for the patients those businesses serve. Treating the two as the same accomplishment lets state legislatures off the hook for the much more concrete, much more fixable problem sitting in their own probation and parole statutes. Nobody needs to wait for Chief Judge Julius's recommendation or a final DEA ruling to close that gap.

New Jersey, Minnesota, and Michigan already demonstrate that protecting medical cardholders under supervision is legally workable today, with existing legislative and judicial tools. It took statutes, not a federal reclassification, to get there. Other states have simply chosen not to write those protections down.

Until legislatures or courts act on a state-by-state basis, whether a legal medical marijuana patient stays free or ends up back in custody depends far less on their diagnosis than on which probation office they happen to report to. That's not a side effect of an imperfect federal policy -- it's a choice being made, or avoided, in fifty separate statehouses.